WallStSmart

Bruker Corporation (BRKR)vsEdwards Lifesciences Corp (EW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 83% more annual revenue ($6.30B vs $3.44B). EW leads profitability with a 17.4% profit margin vs -0.3%. BRKR appears more attractively valued with a PEG of 1.52. EW earns a higher WallStSmart Score of 61/100 (C+).

BRKR

Hold

42

out of 100

Grade: D

Growth: 5.3Profit: 3.5Value: 5.7Quality: 5.3
Piotroski: 2/9

EW

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 7.5Value: 6.0Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BRKRUndervalued (+27.9%)

Margin of Safety

+27.9%

Fair Value

$58.89

Current Price

$44.16

$14.73 discount

UndervaluedFair: $58.89Overvalued
EWUndervalued (+69.7%)

Margin of Safety

+69.7%

Fair Value

$261.90

Current Price

$79.96

$181.94 discount

UndervaluedFair: $261.90Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BRKR1 strengths · Avg: 8.0/10
Price/BookValuation
2.7x8/10

Reasonable price relative to book value

EW2 strengths · Avg: 9.0/10
Operating MarginProfitability
31.2%10/10

Strong operational efficiency at 31.2%

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

Areas to Watch

BRKR4 concerns · Avg: 2.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-0.4%2/10

ROE of -0.4% — below average capital efficiency

Revenue GrowthGrowth
-0.2%2/10

Revenue declined 0.2%

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.044/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
44.7x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-21.10M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : BRKR

The strongest argument for BRKR centers on Price/Book.

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.

Bear Case : BRKR

The primary concerns for BRKR are PEG Ratio, Piotroski F-Score, Return on Equity.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 44.7x leaves little room for execution misses.

Key Dynamics to Monitor

BRKR profiles as a turnaround stock while EW is a growth play — different risk/reward profiles.

BRKR carries more volatility with a beta of 1.12 — expect wider price swings.

EW is growing revenue faster at 16.7% — sustainability is the question.

BRKR generates stronger free cash flow (47M), providing more financial flexibility.

Bottom Line

EW scores higher overall (61/100 vs 42/100), backed by strong 17.4% margins and 16.7% revenue growth. BRKR offers better value entry with a 27.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bruker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Bruker Corporation develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions in the United States, Europe, Asia Pacific, and internationally. The company is headquartered in Billerica, Massachusetts.

Visit Website →

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?